A B S T R A C T The metabolism ofthe fifth component of complement (C5), and its relationship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 ,g/kg per h. In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravasctular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolisim of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suiggesting that in patients with alterna- 
INTRODUCTION
The fifth component of complement (C5)1 is the major component of the final common pathway of complement activation-the membrane attack complex C5-9. The cleavage of C5-the final enzymatic step in the complement sequence-yields a larger fragment, C5b, which binds C6-9 to formn the membrane attack complex, and a smaller fragment, C5a, which has anaphylatoxic and chemotactic activity.
The suibunit structure of C5 is very similar to that of the third component (C3) (1) , and this is reflected by the similarity of the C3 and C5 cleaving enzymes (convertases) which are generated after activation of complement by the classical or alternative pathways. Thus the classical pathway C3 convertase, C4b2a, binds the major cleavage fragment of C3, C3b, to become a C5 convertase C423b.
The mechanism of formation and composition of the alternative pathway C3 and C5 convertases has been the subject of mtuch recent investigation. Upon activation of the alternative pathway C3b is generated and interacts with factors B and D (D cleaving Factor B) in the C3b feedback or amplifica-'Abbreviations used in this paper: B, Factor B (or C3 proactivator or glycine-rich B glycoprotein) of the altemative pathway; C3, third component of complement; C3bINA, C3b inactivator; C5, fifth component of complement; CVF, cobra venom factor; EV/IV ratio, extravascular/intravascular distribution ratio; FCR, fractional catabolic rate; HBAg, hepatitis B antigen; MCGN, mesangiocapillary nephritis; NeF, the C3 nephritic factor; PLD, partial lipodystrophy; SLE, systemic lupus erythematosus; U/P ratio, urine/plasma ratio of radioactivity.
The Journal of Clinical Investigation Volume 59 April 1977 704-715 704 tion cycle to generate the bimolecular C3 convertase C3bBb. C3bBb is also a C5 convertase, but this activity is only expressed if the convertase is generated on a cell surface (rather than in the fluid phase) and contains additional C3b molecules (2, 3) . C3bBb loses activity by intrinsic decay, but it has recently been shown that the plasma protein f1H accelerates this decay by dissociating Bb from the complex and rendering the residual C3b accessible to the C3b inactivator (C3bINA) (4, 5, 6) ; the additional C3b in the solid phase C5 convertase C3bBb is apparently already susceptible to C3bINA, which causes the enzyme to revert to a C3 convertase only (3) .
The half-life of C3bBb is prolonged by activated properdin, which binds to C3b, and by the C3 nephritic factor (NeF) which binds to C3bBb (7, 8) . The convertase thus stabilized by activated properdin is still susceptible to 3l1H but that stabilized by NeF is relatively resistant to ,1H (4) . Furthermore, in the presence of NeF a C3 convertase can be generated, C3bB, which contains uncleaved B (9-11); it is not established whether this latter enzyme is able to cleave C5.
To determine the extent of C5 activation in disease, and to examine the relationship of these in vitro observations to mechanisms of complement activation in vivo-partictularly as C5 concentrations are frequently normal in patients with complement activation-we have studied the metabolism of simultaneously administered radioiodinated C5 and C3 (or in a few cases Factor B) in normal subjects, and in patients with variouis diseases, including those known to involve complement activation.
METHODS
Purification of complement proteins. C5 was purified from pooled normal human serum by the method of Nilsson et al. (12) . The final preparation contained no C3 (or other proteins) on immunoelectrophoresis and Ouchterlony gel analysis against antiwhole human serum (The Wellcome Foundation, Ltd., The Wellcome Research Laboratories, Langley Court, Beckenham, Kent, England) and antihuman C3 antisera and gave a single band on polyacrilamide disk gel electrophoresis and sodium dodecyl sulphate polyacrilamide disk gel electrophoresis. Immunization of rabbits with this preparation of C5 produced an antiserum monospecific for C5 and showing no reactivity against C3.
Factor B and C3 were prepared as previously described (13) . Factor B contained no other proteins by immunoelectrophoresis against antiwhole human serum. All of the several C3 preparations used contained a trace contaminant (probably /31H [14] ) and one a trace amount of IgG, but no other proteins by immunoelectrophoresis against antiwhole human serum.
Radioiodination of proteins. C5, C3, and Factor B were trace labeled by a modification of the chloramine-T method as previously described (15, 16) . C5 was always labeled with 1251, and C3 and Factor B with 1311. Efficiency of labeling ranged from 20 to 40% and specific activity of the labeled proteins up to 1 ,uCi/,ag of protein. Purified human serum albumin (Lister Institute of Preventive Medicine) was added to all preparations to a concentration of 10 mg/ml immediately after labeling. Free radioactivity was removed by one passage down an anion-exchange resin column followed by dialysis until 1% or less of total radioactivity was nonprotein bound. Labeled proteins were subjected to immunoelectrophoresis against antisera to C5, C3, or Factor B and whole human serum, followed by autoradiography. All preparations contained a single radiolabeled protein arc except for one C3 preparation which contained a trace of labeled IgG-this was removed by a Sepharose-coupled monospecific antihuman IgG antibody. (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) Labeled proteins were sterilized by Millipore filtration (Millipore Corp., Bedford, Mass.) and pyrogen-tested in rabbits as previously described (16) .
Functional activity of radiolabeled proteins. C5 and Factor B were functionally assayed by a hemolytic plate technique (13, 17) and C3 by hemolytic titration (13) . No, or only slight, reduction in functional activity per unit of protein occurred on labeling. However because these proteins were trace labeled it could not be assumed that the total functional capacity of a labeled preparation was necessarily representative of the small number of labeled molecules. Therefore, as a further functional test of the labeled molecules, their ability to be turned over by cobra venom factor (CVF) was shown by in vivo tumover studies in rabbits as previously described (18) . Rapid acceleration in turmover of radiolabeled C5, C3, and Factor B occurred after administration of CVF to rabbits which had previously been injected with these proteins (see Fig. 1 ). No such acceleration was seen if inactivated components were used.
Complement component assays. Plasma C5 concentrations were measured by electroimmunoassay ('rocket' technique) with a monospecific rabbit antihuman C5 antibody; concentrations of Clq, C4, C3, and Factor B were measured by single radial immunodiffusion. Factor D was measured functionally by a hemolytic plate technique (17) . C3 splitting activity was detected by crossed immunoelectrophoresis (19) and its capacity to activate the altemative pathway (NeF activity) examined in magnesium EGTA as previously described (20) . The presence of circulating C3d was detected by immunoelectropheresis of fresh EDTA plasma against an antiserum with specificity for C3d (21) .
Protocol for turnover studies. Informed consent was obtained from all patients and control normal subjects. Thyroid uptake of radioiodine was blocked by administration of potassium iodide 180 mg three times daily for 3 days before and during the study or (in iodinesensitive subjects) of potassium perchlorate 1 g 1 h before starting, and 200 mg three times daily during the study. Subjects were given 10-15 ,Ci of 1251-CS and 2-12 ,uCi of '31I-C3 or Factor B intravenously, syringes being weighed before and after injection to calculate the dose of isotope. Venous blood samples were taken into EDTA at 10 min, 4-6 h, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] h, and 26-28 h after injection and daily thereafter for 6-8 days. Blood samples were processed and counted and free and protein bound radioactivity calculated as previously described (16) . Continuous urine collections were obtained throughout the study. In some patients whole body radioactivity for 1311 was measured with a whole body counter (10 6-inch sodium iodide crystals).
Analysis of metabolic data. Metabolic parameters (frac- Subjects. 28 subjects were studied. Seven were normal volunteers from the medical and technical staff. 16 were patients with diseases associated with complement activation; 7 with clinically active systemic lupus erythematosus (SLE); 4 with mesangiocapillary (membranoproliferative) nephritis (MCGN), 2 of whom had associated partial lipodystrophy (PLD); 1 with PLD alone; 1 with acute poststreptococcal nephritis; 1 with recurrent skin lesions, angioedema and classical pathway complement activation (previously reported by us [24] ); 1 with subacute Q Fever (Coxiella) endocarditis, and 1 with essential mixed cryoglobulinemia. Of the remaining 5 patients, 2 had end stage chronic renal failure without evidence of complement activation, 1 minimal-change nephritis, and 1 myasthenia gravis. Patient 17 had chronic active hepatitis and hepatitis B (HBAg) antigenemia, and was given two intravenous infusions of hepatitis B antibody during the period of study in a therapeutic attempt to eliminate the HBAg.
Five of the above subjects (one normal, one SLE, one MCGN, and the patients with angioedema and mixed cryoglobulinemia) were injected with '31I Factor B and '25I-C5; all the remaining subjects were injected with 131I-C3 and 125IC5.
RESULTS
Normal subjects (Table I ). The metabolic data for C5 in seven and for C3 in six normal subjects are given in Table I . The values for FCR, EV/IV ratios, and t1/2 were similar for both proteins; it can be seen that the three methods of analysis used gave very similar values for FCR, and EV/IV ratios calculated by Matthews Patient 17 with HB antigenemia with hepatitis B antibody during the tu As is apparent from Fig. 2 there was iI over of C3, and to a lesser extent C two periods of infusion (presumably i formation of circulating immune corr study also provided additional in viv( the functional activity of both proteins. jects in Table I . However, an exception was shown by some patients (patients 4, 8, 11 , 12, and 13) in whom U/P ratios for C3 decreased progressively throughout the study; in these patients there was also a tendency for their plasma disappearance curves not to reach a final monoexponential slope. This has been previously described by us and attributed to the presence of labeled C3d in the circulation (21) . However, this phenomenon was never observed with C5, U/P ratios remaining relatively constant, although a nonlinear plasma disappearance curve was observed in patient 8 in whom C5 catabolism was very rapid.
-. " 125l C5 In this patient values for FCR and U/P ratios could not be calculated because of impaired renal function.
1311 C3 Fig. 3 No patient had values for C5 synthesis unequivocally below the normal range but three (patients 1, 2, and 13) had low values for C3 synthesis.
Distribution of C5 and C3. EV/IV ratios were calculated by the methods of Matthews and Nosslin; there was less agreement between the values obtained by these two methods in patients than in normals. In Nosslin's analysis the size of the EV pool is derived by subtraction of plasma radioactivity from whole body activity-the latter being obtained by subtraction of cumulative urine excretion of free radioiodine from the dose of isotope (23) . The value for the EV/IV ratio obtained by Matthews' method is dependent on the shape of the initial portion of the plasma disappearance curve and urine data are not used (22) . The presence of aggregated protein would increase the value, and it is necessary to obtain multiple early blood samples to plot the initial portion of the curve accurately. Thus, in studying distribution, values obtained by Nosslin's analysis have been used as being theoretically more accurate -furthermore only patients with accurate urine collections and with no cumulation of free plasma radioiodine have been included (iodide retention due to impaired renal function, or incomplete urine collections would tend to artefactually increase the size of the EV pool). In five patients where whole body radioactivity for 131I was measured with the whole body counter there was close agreement with the values obtained with urine excretion of iodide as described above.
The relationship between the distribution of C3 and C5 with values thus obtained, is shown in Fig.  5 . There was always increased EV distribution of C3 compared to controls and in patients with SLE there was a similar increase in EV distribution of C5. However in patients with MCGN there was increased EV distribution of C3 but the EV/IV ratios for C5 all fell within the normal range (al- O normal subjects; 0 patients; there is no significant correla- FIGURE 5 Relationship between EV/IV ratio of C5 and C3 (or B). Table II. nearly always less than that of C3 in patients with complement activation. They also show that C5 turnover may be normal, or near normal, despite greatly increased C3 turnover, particularly in patients with NeF in their serum. Finally they show that in many patients with complement activation there is increased extravascular distribution of C5, and C3, and strongly suggest that there is also extravascular catabolism of C5 and C3, particularly in patients with SLE. C5 and C3 catabolism. There has to our knowledge been no previous study of the relationship between C3 and C5 turnover, or any studies of C5 turnover apart from those of Ruddy et al. (26) . In a large series of complement protein turnovers the latter authors include C5 turnovers in three normal subjects and five patients. The FCR of C5 in our normal subjects accords with their findings and is similar to that found for C3 (21, (26) (27) (28) (29) , Factor B (21), and C4 (26) in previous studies by ourselves and others; complement proteins have a rapid tuirnover relative to other serum proteins, the mechanism of this normal turnover being unknown although there is some evidence against it being due to low level activation of the system (21) .
The catabolism of labeled proteins is obviously affected by the presence of denatured and altered protein and the difficulties of assessing the functional activity of trace labeled complement proteins have already been discussed. However, we are confident that the radioiodinated C5 used in these studies contained little or no denatured material in view of the tests already mentioned, the narrow normal range for FCR, expected plasma volumes and capacity of the labeled protein to show accelerated turnover in vivo as shown in Fig. 2 (17) .
In fact there is great difficulty in relating the absolute amounts of C3 and C5 turned over in vivo, since for each protein there will be a normal route of catabolism which is probably distinct from complement activation (the argument that this is the case for C3 has been previously discussed-21); absolute catabolic rates will reflect both normal and abnormal catabolism and cannot readily be compared in states of C3 activation since the absolute amount of C3 turned over may be reduced because of impaired C3 synthesis. However elevation of fractional catabolic rates appears to be a better guide to abnormal catabolism, as is the case generally for plasma proteins. One way of approaching this problem would be to restrict analysis to EV catabolism, which appears only to occur to any extent in disease. Dissociation of EV C3 and C5 catabolism can be detected as shown in our studies, lending support to there being a real difference in metabolic behavior of the two proteins in disease.
The mechanism of generation and composition of the alternative pathway C3 and C5 convertases is the subject of considerable recent and current research, as outlined in the introduction. The principal C3 convertase of the alternative pathway and the C3b feedback cycle is C3bBb and, as discussed, additional C3b is required for this enzyme to become a C5 convertase and the two forms of the enzyme differ in their susceptibility to C3bINA. The mechanisms by which the alternative pathway is activated, and the initial C3b generated, are still incompletely understood. At present it appears that native C3, trace amounts of C3b, Factor B, and Factor D interact together to generate a supply of C3b (11, 30) ; another protein which may be involved in alternative pathway activation is a f8-pseudoglobulin present in normal serum, which shows some analogies to NeF and has recently been described by Schreiber and colleagues (31) who have termed it initiating factor. These experimental observations suggest several factors, in addition to those already mentioned in the context of the classical pathway, which might theoretically favor greater C3 than C5 conversion by the alternative pathway. These are: firstly that fluid phase C3bBb is not a C5 convertase (2); secondly that additional C3b is required for C3bBb to become a C5 convertase (2, 3)-consumption or reduced synthesis of C3, by whatever mechanism, might thus limit its availability for C5 convertase formation; and thirdly that the additional C3b in the C5 convertase is susceptible to C3bINA, while that in the bimolecular convertase is not (3), which might tend to accelerate decay of the C5 convertase, relative to the C3 convertase, in vivo.
Hence several different situations might theoretically exist in vivo with respect to C3, Factor B, and C5 turnover, and our studies suggest that this is in fact the case. Thus the patients with SLE all showed increased fractional catabolism of C3 and C5, presumably restulting from activation of the classical pathvay: however in three patients with evidence of classical pathway activation (low Clq or C4 in patients 14, 15, and 16) C5 turnover was normal despite moderately increased turnover of C3 or B-the reason for this discrepancy is unclear. Some of the patients with MCGN also showed increased C5 as well as increased C3 or B turnover; in one (patient 8) this was associated with evidence of classical pathway activation by immune complexes, and it has previously been shown that some patients with MCGN, particularly the type associated with subendothelial deposits on electron microscopy, have evidence of classical pathway activation (20) . The only patients in this series with unequivocal alternative pathway activation are the two with MCGN or PLD, and NeF in their serum, and it is noteworthy that in two studies in these patients C5 turnover was normal despite greatly increased fractional turnover of C3. This suggests that, for some of the reasons mentioned above, little or no C5 convertase is being generated in these cases; in particular NeF would tend to generate C3bBb (NeF) in the fluid Metabolism of C5 and C3
phase, and any cell bound C5 convertase formed and stabilized by NeF would still be susceptible to C3bINA, whereas C3 convertase stabilized by NeF would be resistant to the effects of 8lH and C3bINA (3, 4) . A further theoretical possibility is that the enzyme C3bB, containing uncleaved B and therefore unlikely to convert C5, is being generated by NeF.
Although it seems unlikely that the latter enzyme could exist for long in vivo in the presence of the B cleaving enzyme Factor D), which was present in normal amounts in these patients' serum, we have previously reported a patient with MCGN and NeF who had normal Factor B turnover, despite increased C3 turnover (21) . These differences in C3 and C5 metabolism in patients with MCGN emphasize that they are a heterogeneous group, and that this histological category embraces nephritis which may be produced by differing pathogenic mechanisms and accompanied by differing types of complement activation (20) .
Distribution of C3 and C5. The increased EV distribution of C5 in patients with complement activation is of interest and was associated with increased EV distribution of C3, the latter also having been observed in our previous study (21) . We recognize that there are difficulties in deriving reliable estimates of pool size and distribution from protein turnover studies (as discussed above and in reference (23) . However the advantages of Nosslin's method of analysis and the exclusion of patients with iodide retention or incomplete urine collections increase the validity of these observations. This increased EV distribution, even when the total pool of C5 was apparently normal, was particularly marked in patients with SLE and was the most consistently abnormal parameter in these patients; there was also evidence of increased EV catabolism of C5 and C3 in this group.
In patients with MCGN there was a lesser increase in EV distribution of C3 (with the exception of one patient) and the values for EV/IV ratios for C5 fell within the normal range. Where EV catabolism could be estimated it was increased in only one case for C3, and two for C5 (Fig. 7) ; in the two patients with MCGN or PLD and NeF (11A and 12), who had normal FCR of C5, there was no EV catabolism of C5 despite EV catabolism of C3, presumably reflecting the absence of C5 activation. This disparity in EV distribution of C5 between patients with MCGN and those with SLE, even where the FCR of C5 is comparable, may reflect differences in the mode of complement activation in the two groups. The scale of the increase in EV distribution in patients with SLE, and the disparity observed between EV/IV ratios for C3 and C5 in some patients with MCGN and PLD indicate that these alterations in distribution are specific consequences of the underlying immunopathological process in SLE and MCGN, rather than nonspecific changes resulting from a generalized increase in vascular permeability to plasma proteins. CONCLUSION These differences in metabolic parameters for C5 between patients with SLE and those with MCGN and NeF presumably reflect the different mechanisms of complement activation in these two groups. In SLE the increased catabolism and EV distribution of C3 and C5 suggest that both proteins are playing a role in inflammatory tissue injury, whereas the failure to activate C5 and normal C5 distribution, in the patient with PLD may possibly explain the lack of overt tissue inflammation in such cases (32) .
Combination of such in vivo studies as these, with in vitro work with isolated proteins, should enhance understanding of the relevance of both types of experimental approach to complement metabolism.
